Quanterix (QTRX) AI Stock Analysis

• Market Cap: $245.80M
• Dividend Yield: N/A
• Average Volume (3M): 509.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -2.74%
• EPS Growth: -96.96%
• Country: US
• Employees: 471
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.77
• Shares Outstanding: 46,465,916
• 10 Day Avg. Volume: 461,526
• 30 Day Avg. Volume: 509,801
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.13
• Enterprise Value/Revenue: 0.26
• Enterprise Value/Gross Profit: 0.47
• Enterprise Value/Ebitda: -0.39
• 1Y Price Target: $5.92
• Price Target Upside: 11.91% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $5.50 ▲(3.97% Upside)

Quanterix's overall stock score reflects significant financial challenges, with declining revenues and cash flow issues being the most critical factors. While strategic initiatives and potential long-term growth from the Akoya acquisition offer some optimism, immediate financial and operational hurdles remain substantial.

Positive Factors

Strategic Acquisitions

The Akoya acquisition is expected to drive long-term growth and value creation through synergy savings and a stronger market position, enhancing Quanterix's competitive edge in the biotechnology sector.

Market Expansion

By expanding its addressable market, Quanterix positions itself for significant growth opportunities, tapping into larger sectors and increasing its potential customer base, which can lead to sustainable revenue growth.

Product Innovation

The Simoa One platform expansion is set to significantly increase Quanterix's market reach and installed base, creating substantial high-margin growth opportunities and reinforcing its technological leadership in biomarker detection.

Negative Factors

Revenue Decline

A significant year-over-year revenue decline highlights ongoing financial challenges and market uncertainties, which could impact Quanterix's ability to invest in growth and maintain competitive positioning.

Increased Operating Expenses

Rising operating expenses, including costs related to acquisition and restructuring, could strain Quanterix's financial resources, limiting its ability to achieve profitability and invest in future growth initiatives.

Decline in Instrument Revenue

A decline in instrument revenue indicates challenges in product sales and market penetration, which may affect Quanterix's revenue streams and hinder its ability to capitalize on its technological innovations.

Quanterix Business Overview & Revenue Model

Company Description

Quanterix Corporation (QTRX) is a biotechnology company that focuses on advancing the field of precision medicine through its innovative technology platform. The company specializes in ultra-sensitive biomarker detection and analysis, enabling researchers and clinicians to better understand and diagnose diseases. Quanterix operates primarily in the life sciences sector, offering products and services that include their Simoa (Single Molecule Array) technology, which allows for the measurement of low-abundance biomarkers in various applications such as oncology, neurology, and cardiology.

How the Company Makes Money

Quanterix generates revenue through the sale of its proprietary Simoa technology systems, consumables, and related services to academic, pharmaceutical, and biotechnology companies. The company has multiple key revenue streams, including instrument sales, which provide upfront revenue, and ongoing sales of consumables that are required for the operation of their systems. Additionally, Quanterix earns revenue from service contracts and collaborations with pharmaceutical companies for specialized biomarker analysis and clinical trials. Strategic partnerships with major research institutions and pharmaceutical companies further contribute to its earnings through collaborative research agreements and co-development projects that leverage Quanterix's technology for drug development and biomarker discovery.

Quanterix Financial Statement Overview

Summary

Quanterix shows revenue growth but struggles with profitability, as indicated by negative net income and EBIT margins. The balance sheet is strong with low debt, but negative cash flows highlight operational challenges.

Income Statement

The company has shown revenue growth over several years, but profitability is a concern with consistently negative net income and EBIT margins. Gross profit margin is relatively stable, but high operating losses impact overall performance.

Balance Sheet

The balance sheet is solid with a healthy equity base and low debt levels, as indicated by a low debt-to-equity ratio. However, the company is not yet generating positive returns on equity due to ongoing net losses.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow has shown some improvement but remains negative, indicating the company is not yet self-sustaining.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	125.38M	137.42M	122.37M	105.52M	110.56M	86.38M
Gross Profit	69.64M	81.12M	70.65M	46.24M	61.73M	48.18M
EBITDA	-84.62M	-44.26M	-15.63M	-91.88M	-53.24M	-27.27M
Net Income	-70.50M	-38.53M	-32.33M	-96.70M	-57.69M	-31.53M
Balance Sheet
Total Assets	375.61M	406.53M	425.01M	434.20M	501.53M	271.05M
Cash, Cash Equivalents and Short-Term Investments	261.17M	289.12M	321.32M	338.74M	396.46M	181.58M
Total Debt	35.53M	37.37M	41.46M	44.10M	21.89M	30.80M
Total Liabilities	83.15M	76.50M	78.08M	75.26M	60.58M	64.92M
Stockholders Equity	292.46M	330.04M	346.93M	358.94M	440.95M	206.13M
Cash Flow
Free Cash Flow	-32.89M	-38.53M	-22.69M	-60.00M	-61.52M	-27.30M
Operating Cash Flow	-29.59M	-35.16M	-18.90M	-48.27M	-47.91M	-23.36M
Investing Cash Flow	114.60M	-82.27M	-148.40M	-11.21M	-6.34M	-626.00K
Financing Cash Flow	-151.00K	456.00K	2.69M	2.31M	270.80M	96.24M

Quanterix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.29
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTRX, the sentiment is Negative. The current price of 5.29 is below the 20-day moving average (MA) of 5.69, above the 50-day MA of 5.29, and below the 200-day MA of 6.10, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 44.47 is Neutral, neither overbought nor oversold. The STOCH value of 22.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QTRX.

Quanterix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	―	$254.82M	19.39	10.79%	―	17.11%	45.34%
MASS	―	$286.16M	―	-46.85%	―	14.65%	-86.36%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QTRX	―	$245.80M	-2.91	-22.27%	―	-2.74%	-96.96%
OM	―	$230.86M	―	-87.65%	―	2.47%	56.93%
TLSI	―	$234.87M	―	―	―	45.50%	53.07%
NNOX	―	$217.43M	―	-32.87%	―	17.36%	9.38%

Quanterix Corporate Events

Quanterix Approves Key Governance Changes at Annual Meeting

On September 29, 2025, Quanterix Corporation held its Annual Meeting of Stockholders, where several key proposals were approved. These included the election of three independent directors, approval of executive compensation, ratification of KPMG as the accounting firm, and amendments to the company’s Charter to declassify the board and eliminate supermajority voting requirements. These changes are expected to streamline governance and potentially enhance shareholder influence in corporate decisions.

The most recent analyst rating on (QTRX) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Quanterix Earnings Call: Strategic Gains Amid Financial Hurdles

Quanterix’s recent earnings call presented a mixed sentiment, reflecting both strategic progress and financial challenges. The company highlighted significant advancements, such as the Akoya acquisition and market expansion, yet faced declines in revenue and sales, particularly in the academic and pharmaceutical sectors. While Quanterix is actively pursuing cost optimization and future growth, it currently grapples with notable short-term financial hurdles.

Quanterix Reports Q2 2025 Financial Results

Quanterix Corporation, a leader in ultra-sensitive biomarker detection, operates in the biotechnology sector, focusing on disease research, diagnostics, and drug development. The company recently announced its financial results for the second quarter of 2025, highlighting its strategic acquisition of Akoya Biosciences and advancements in Alzheimer’s diagnostics.

Quanterix Adopts New Bylaws Amid Financial Challenges

On August 5, 2025, Quanterix‘s Board of Directors adopted new bylaws to implement a majority voting standard for uncontested director elections. The company also announced financial results for the second quarter of 2025, reporting a revenue decrease of 29% compared to the previous year and a net loss of $30 million. Despite these challenges, Quanterix highlighted significant growth in its Alzheimer’s Diagnostics revenues and strategic actions aimed at long-term growth, including the completion of its acquisition of Akoya Biosciences. The company is focused on achieving cash flow breakeven in 2026 and expects to exit 2025 with approximately $120 million in cash and cash equivalents.

The most recent analyst rating on (QTRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Quanterix Announces Cooperation Agreement with Kent Lake

On August 4, 2025, Quanterix Corporation announced a cooperation agreement with Kent Lake Partners LP to appoint a new independent director by December 1, 2025, and to seek shareholder approval to declassify its board. This agreement includes amending bylaws for a majority voting standard in uncontested elections and Kent Lake’s withdrawal of previous director nominations and proposals. The collaboration aims to enhance governance and focus on the company’s strategic goals, potentially benefiting stakeholders and positioning Quanterix for continued success.

The most recent analyst rating on (QTRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.